NASDAQ:RADX

Radiopharm Theranostics (RADX) Stock Price, News & Analysis

Radiopharm Theranostics logo
$0.63 -0.04 (-6.33%)
Closing price 11/20/2026 03:55 PM Eastern
Extended Trading
$0.60 -0.03 (-5.14%)
As of 11/20/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Radiopharm Theranostics Stock (NASDAQ:RADX)

Advanced

Key Stats

Today's Range
$0.63
▼
$0.72
50-Day Range
$0.63
▼
$2.01
52-Week Range
$0.63
▼
$16.25
Volume
12,983 shs
Average Volume
49,366 shs
Market Capitalization
$9.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00
Consensus Rating
Hold

Company Overview

Radiopharm Theranostics is an Australian clinical-stage biotechnology company developing radiopharmaceuticals for cancer imaging and treatment. Its theranostic approach uses radioactive compounds designed to help identify cancer and, in some cases, deliver targeted radiation to tumors.

The company’s research programs span several types of targeting agents, including peptides, small molecules, antibodies and nanobodies. Its pipeline includes candidates in development for imaging or treating cancers such as brain, breast and kidney cancer.

Radiopharm conducts research and clinical development through programs in Australia and internationally. Its products remain under development and are not established commercial treatments.

AI Generated. May Contain Errors.

Radiopharm Theranostics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
59th Percentile Overall Score

RADX MarketRank™: 
2.94138269527 of 5 stars

Radiopharm Theranostics scored higher than 59% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Radiopharm Theranostics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Radiopharm Theranostics has a consensus price target of $11.00, representing about 1,644.9% upside from its current price of $0.63.

  • Amount of Analyst Coverage

    Radiopharm Theranostics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Radiopharm Theranostics' stock forecast and price target.
  • Price to Book Value per Share Ratio

    Radiopharm Theranostics has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.86% of the float of Radiopharm Theranostics has been sold short.
  • Short Interest Ratio / Days to Cover

    Radiopharm Theranostics has a short interest ratio ("days to cover") of 4.53.
  • Change versus previous month

    Short interest in Radiopharm Theranostics has recently decreased by 5.29%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Radiopharm Theranostics does not currently pay a dividend.

  • Dividend Growth

    Radiopharm Theranostics does not have a long track record of dividend growth.

  • News Sentiment

    Radiopharm Theranostics has a news sentiment score of -0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Radiopharm Theranostics this week, compared to 2 articles on an average week.
  • Search Interest

    1 people have searched for RADX on MarketBeat in the last 30 days.
  • MarketBeat Follows

    1 people have added Radiopharm Theranostics to their MarketBeat watchlist in the last 30 days.
Receive RADX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Radiopharm Theranostics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RADX Stock News Headlines

Radiopharm Theranostics (NASDAQ:RADX) Stock Jumps 2.1% - Here's Why
CFA: Bank of America Said THIS
On January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing.tc pixel
Radiopharm Theranostics Reports Business Update
See More Headlines

RADX Stock Analysis - Frequently Asked Questions

Radiopharm Theranostics' stock was trading at $5.22 on January 1st, 2026. Since then, RADX shares have decreased by 87.9% and is now trading at $0.6304.

Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX) released its quarterly earnings results on Friday, July, 31st. The company reported ($0.81) earnings per share (EPS) for the quarter. The business earned $494.49 thousand during the quarter.

Shares of RADX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
7/31/2026
Today
11/22/2026
Fiscal Year End
6/30/2027

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:RADX
CIK
1949257
Fax
N/A
Employees
14
Year Founded
N/A

Price Target and Rating

High Price Target
$16.00
Low Price Target
$6.00
Potential Upside/Downside
+1,644.9%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.16
Quick Ratio
1.16

Sales & Book Value

Annual Sales
$2.77 million
Price / Sales
3.58
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.28 per share
Price / Book
0.49

Miscellaneous

Outstanding Shares
15,703,000
Free Float
N/A
Market Cap
$9.90 million
Optionable
N/A
Beta
2.07
7 Stocks That Could Be Bigger Than Tesla, NVIDIA, and Google Cover

Could the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.

Get This Free Report

This page (NASDAQ:RADX) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners